Skip to content
The Policy VaultThe Policy Vault

Releuko — Medica

Acute Myeloid Leukemia (AML) in a patient receiving chemotherapy

Initial criteria

  • Prescribed by or in consultation with an oncologist or hematologist

Approval duration

6 months